RHP (RHP)

$5.7B
Market Cap
24.1
P/E Ratio
1.19
Beta
5.19%
Dividend Yield
Piotroski 4/9Altman Z 1.2 DistressBeneish M -2.54 CleanROIC−WACC -1.8%

Quantitative Summary

Deterministic

Financial health is average: Piotroski 4/9, Altman Z 1.2.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation efficiency of RHP reveals a distinct divergence between return on invested capital and shareholder returns, driven primarily by financial leverage rather than operational superiority. While the ROIC-WACC spread sits at 7.0%, indicating modest value creation relative to cost of capital, the DuPont decomposition shows that an equity multiplier of 5.10x is the primary engine behind a 20.1% ROE; this high leverage magnifies returns but simultaneously amplifies downside risk if asset utilization falters. The Piotroski F-Score of 4/9 suggests moderate financial strength with potential weaknesses in profitability or liquidity trends, yet the negative Beneish M-Score of -2.54 provides a counterweight by signaling low probability of earnings manipulation and reinforcing the credibility of the reported net margin of 9.4%.

Valuation metrics position RHP at a premium relative to its growth trajectory, with a current P/E of 24.1x implying that the market prices in significant future expansion beyond the recent 10.2% revenue growth rate. Although no explicit DCF fair value or historical percentile data is provided for direct comparison, the multiple suggests investors are anticipating acceleration in asset turnover or margin expansion to justify the current pricing. The gap between the modest ROIC and the elevated valuation multiple indicates that market expectations rely heavily on the sustainability of the 31.5% gross margin and the ability to maintain high equity leverage without triggering solvency concerns, rather than immediate fundamental improvements in operational efficiency.

Insider activity over the last ninety days shows $785,226 net buying, which aligns with a management perspective that may view current levels as attractive despite the elevated multiple. However, this insider flow must be weighed against the structural risks inherent in the 5.10x equity multiplier and the middling Piotroski score; while insiders are accumulating shares, the company's fundamental quality does not yet reflect high-grade investment characteristics typically associated with strong F-scores or robust ROIC spreads. The risk/reward profile appears balanced between insider confidence in near-term prospects and the mathematical vulnerabilities introduced by aggressive leverage and moderate operational scores.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

4/9
Piotroski F-Score
Average — mixed operational signals
1.2
Altman Z-Score
Distress Zone — below 1.8 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.54
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

31.5%
Gross Margin
9.4%
Net Margin
7.0%
ROIC
8.8%
WACC
ROIC − WACC Spread: -1.8%— Negative spread.
+10.2%
Revenue Growth (YoY)
-10.4%
Earnings Growth (YoY)
232.4M
Free Cash Flow
123%
FCF Payout Ratio

⚠️ Dividend consumes >80% of FCF — sustainability risk.

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

9.4%
Net Profit Margin
NI ÷ Revenue
×
0.42x
Asset Turnover
Revenue ÷ Assets
×
5.10x
Equity Multiplier
Assets ÷ Equity
=
20.1%
Return on Equity
⚠️ High equity multiplier — ROE is being amplified by leverage, not operational excellence.

Balance Sheet Health

4.10x
Debt / Equity
1.24x
Current Ratio
2.1x
Interest Coverage
4.5x
Net Debt / EBITDA
2.51%
FCF Yield
774.0M
EBITDA

Insider Activity (Last 90 Days)

Net Insider Flow
+$785,226
Net Buying
1
Buy Transactions
0
Sale Transactions
2026-03-13REED COLIN VERNONOther28,409 shares
2026-03-13FIORAVANTI MARKOther40,888 shares
2026-03-13LYNN SCOTT JOther7,102 shares
2026-03-13HUTCHESON JENNIFER LOther10,794 shares
2026-03-13CHAFFIN PATRICK SOther8,834 shares

Open-market buys vs sells by company insiders. Source: yfinance.

Earnings Surprise History

Q3
✓ Beat
Est: $0.63
Act: $1.02
+61.7%
Q2
✓ Beat
Est: $0.47
Act: $0.59
+23.3%
Q1
✓ Beat
Est: $1.21
Act: $1.35
+11.6%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

19.9
Forward P/E
PEG Ratio
7.56
Price/Book
490952
Avg Volume
$105.75
52W High
$76.27
52W Low
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$621M
Tracked Passive Exposure
8
ETFs Holding RHP
0.15%
Avg Weight in ETFs
$405B
Total ETF AUM

When investors buy or sell ETFs like SLYG or SPSM, the fund manager is mechanically forced to buy or sell RHP shares regardless of RHP's individual fundamentals. We estimate $621M of passive capital is structurally linked to RHP through 8 tracked ETFs. Passive flows have a limited but growing influence on RHP's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in RHP to visualize passive redemption contagion across ETFs and collateral stocks.

RHP Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
RHPEpicenterVBETFVXFETFVNQETFVRTPXUnknownWELLLow RiskPLDMed RiskEQIXMed RiskAMTHigh Risk
RHP Price Drop (%)0

If RHP (RHP) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Vanguard Real Estate II Index Fund Institutional Plus Shares (VRTPX) as the most exposed collateral stock, sharing 1 ETFs with RHP. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 8 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

RHP Ownership Dynamics

Ticker
RHP

Float lock-up computed from 8 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

RHP Capital Efficiency

How efficiently does RHP convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$232M
EBITDA
$774M
FCF Conversion
30%
Reinvestment Rate
70%
30% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
7.0%
ROIC − WACC Spread
-1.8%

RHP converts 30% of its EBITDA into free cash flow, a moderate conversion rate — significant EBITDA is consumed by capital expenditures, working capital changes, or interest payments. The 70% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-1.8%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-04-142,186$101.70$222,316.2
2026-03-3111,133$91.17$1.0M
2026-03-174,793$91.47$438,415.71
2026-03-0916$95.81$1,532.96
2026-02-2347$104.85$4,927.95
2026-02-1970$102.13$7,149.1
2026-02-1313,279$100.20$1.3M
2026-02-10591$97.94$57,882.54
2026-02-09453$97.96$44,375.88
2026-02-02839$94.70$79,453.3
2026-01-27788$95.66$75,380.08
2026-01-124$95.00$380
2026-01-0881$91.93$7,446.33
2025-12-31600$96.87$58,122
2025-12-2680$97.69$7,815.2
2025-12-1239$96.76$3,773.64
2025-12-103$91.77$275.31
2025-12-0831$91.74$2,843.94
2025-11-26383$96.12$36,813.96
2025-11-137,180$94.41$677,863.8
2025-11-0682$92.27$7,566.14
2025-10-3098$86.65$8,491.7
2025-10-281,359$87.50$118,912.5
2025-10-142,242$88.89$199,291.38
2025-10-1043$88.86$3,820.98
2025-10-0273$89.38$6,524.74
2025-10-0115,530$89.59$1.4M

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare RHP to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.